Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma

doi:10.4251/wjgo.v12.i6.663

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9429)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

597

WORD

233

HTML

5223

Figures (1-4)

426

Tables (1-3)

370

Sum=6849

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

924

Download

1656

Sum=2580

Jun 15, 2020 (publication date) through Dec 20, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Jun 15, 2020; 12(6): 663-676
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.663

Table 2 Tumor response (modified Response Evaluation Criteria for Solid Tumors)

Best tumor response	Participants, n (%)
DCR, CR + PR + SD	58 (87.9)
ORR, CR + PR	28 (42.4)
CR	9 (13.6)
PR	19 (28.8)
SD	30 (45.5)
PD	8 (12.1)

All participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma. CR: Complete response; DCR: Disease control rate; PR: Partial response; SD: Stable disease; ORR: Objective response rate.

Citation: Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676
URL: https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.663